1. Home
  2. MRBK vs TLSI Comparison

MRBK vs TLSI Comparison

Compare MRBK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meridian Corporation

MRBK

Meridian Corporation

HOLD

Current Price

$19.94

Market Cap

228.9M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.14

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRBK
TLSI
Founded
2004
2010
Country
United States
United States
Employees
N/A
102
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.9M
270.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
MRBK
TLSI
Price
$19.94
$4.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$20.75
$7.00
AVG Volume (30 Days)
94.9K
315.3K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
3.05%
N/A
EPS Growth
30.34
N/A
EPS
0.17
N/A
Revenue
$6,316,000.00
N/A
Revenue This Year
$25.40
$35.45
Revenue Next Year
$8.15
$37.58
P/E Ratio
$115.00
N/A
Revenue Growth
10.13
N/A
52 Week Low
$11.87
$2.20
52 Week High
$21.59
$7.95

Technical Indicators

Market Signals
Indicator
MRBK
TLSI
Relative Strength Index (RSI) 65.72 58.37
Support Level $18.32 $3.70
Resistance Level $20.74 $4.50
Average True Range (ATR) 0.58 0.35
MACD 0.07 0.09
Stochastic Oscillator 76.02 77.57

Price Performance

Historical Comparison
MRBK
TLSI

About MRBK Meridian Corporation

Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: